Nergiz Dagoglu1, Elena Nedea1, Vitaliy Poylin1, Deborah Nagle1, Anand Mahadevan1. 1. 1 Department of Radiation Oncology, Istanbul University, Istanbul, Turkey ; 2 Radiation Oncology, 3 Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: The incidence of positive margins after neoadjuvant chemoradiation and adequate surgery is very low. However, when patients do present with positive or close margins, they are at a risk of local failure and local therapy options are limited. We evaluated the role of stereotactic body radiotherapy (SBRT) in patients with positive or close margins after induction chemoradiation and total mesorectal excision. METHODS: This is a retrospective evaluation of patients treated with SBRT after induction chemoradiation and surgery for positive or close margins. Seven evaluable patients were included. Fiducial seeds were place at surgery. The Cyberknife(TM) system was used for planning and treatment. Patients were followed 1 month after treatment and 3-6 months thereafter. Descriptive statistics and Kaplan-Meir method was used to repot the findings. RESULTS: Seven patients (3 men and 4 women) were included in the study with a median follow-up of 23.5 months. The median initial radiation dose was 5,040 cGy (in 28 fractions) and the median SBRT dose was 2,500 cGy (in 5 fractions). The local control at 2 years was 100%. The overall survival at 1 and 2 years was 100% and 71% respectively. There was no Grade III or IV toxicity. CONCLUSIONS: SBRT reirradiation is an effective and safe method to address positive or close margins after neoadjuvant chemoradiation and surgery for rectal cancer.
BACKGROUND: The incidence of positive margins after neoadjuvant chemoradiation and adequate surgery is very low. However, when patients do present with positive or close margins, they are at a risk of local failure and local therapy options are limited. We evaluated the role of stereotactic body radiotherapy (SBRT) in patients with positive or close margins after induction chemoradiation and total mesorectal excision. METHODS: This is a retrospective evaluation of patients treated with SBRT after induction chemoradiation and surgery for positive or close margins. Seven evaluable patients were included. Fiducial seeds were place at surgery. The Cyberknife(TM) system was used for planning and treatment. Patients were followed 1 month after treatment and 3-6 months thereafter. Descriptive statistics and Kaplan-Meir method was used to repot the findings. RESULTS: Seven patients (3 men and 4 women) were included in the study with a median follow-up of 23.5 months. The median initial radiation dose was 5,040 cGy (in 28 fractions) and the median SBRT dose was 2,500 cGy (in 5 fractions). The local control at 2 years was 100%. The overall survival at 1 and 2 years was 100% and 71% respectively. There was no Grade III or IV toxicity. CONCLUSIONS: SBRT reirradiation is an effective and safe method to address positive or close margins after neoadjuvant chemoradiation and surgery for rectal cancer.
Entities:
Keywords:
Stereotactic body radiotherapy (SBRT); positive margin; reirradiation
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Anand Mahadevan; Scott Floyd; Eric Wong; Suriya Jeyapalan; Michael Groff; Ekkehard Kasper Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-13 Impact factor: 7.038
Authors: Wijnand J Alberda; Cornelis Verhoef; Joost J Nuyttens; Joost Rothbarth; Esther van Meerten; Johannes H W de Wilt; Jacobus W A Burger Journal: Ann Surg Oncol Date: 2013-10-12 Impact factor: 5.344
Authors: Sarahgene G Defoe; Mark E Bernard; Jean-Claude Rwigema; Dwight E Heron; Cihat Ozhasoglu; Steven Burton Journal: J Cancer Res Ther Date: 2011 Oct-Dec Impact factor: 1.805
Authors: B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner Journal: J Natl Cancer Inst Date: 1988-03-02 Impact factor: 13.506
Authors: Stanley K T Yu; Aneel Bhangu; Diana M Tait; Paris Tekkis; Andrew Wotherspoon; Gina Brown Journal: Cancer Med Date: 2013-12-16 Impact factor: 4.452
Authors: F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt Journal: World J Surg Date: 2009-07 Impact factor: 3.352